We are actively exploring additional opportunities to leverage our pan-variant targeted therapy approach to address treatment resistant cancers.

Our structure-guided drug design approach, integrated with our predictive resistance assay (PRA), allows us to efficiently design and validate novel inhibitors that target all major activating and resistance mutations for a given target. We are currently evaluating several potential targets for a next-generation inhibitor against a clinically validated driver oncogene.

We intend to nominate at least one of these inhibitors as our next program in 2022.